Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Avrobio Inc (NQ: AVRO )

1.475 -0.005 (-0.34%)
Streaming Delayed Price Updated: 2:41 PM EDT, May 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Avrobio Inc

< Previous 1 2 3 Next >
AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome
From AVROBIO, Inc.
Via Business Wire
AVROBIO Announces the Appointment of Essra Ridha, M.D., MRCP, FFPM, as Chief Medical Officer
From AVROBIO, Inc.
Via Business Wire
AVROBIO to Present at the Jefferies Virtual Gene Therapy/Editing Summit
From AVROBIO, Inc.
Via Business Wire
AVROBIO Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry and Gaucher Disease Type 1
From AVROBIO, Inc.
Via Business Wire
AVROBIO to Present New Clinical and Preclinical Data Across Multiple Programs at the ESGCT 28th Annual Congress
From AVROBIO, Inc.
Via Business Wire
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
AVROBIO to Participate at Four Upcoming Investor Conferences
From AVROBIO, Inc.
Via Business Wire
AVROBIO Reports Second Quarter 2021 Financial Results and Provides Business Update
From AVROBIO, Inc.
Via Business Wire
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
AVROBIO to Present at Two Upcoming Investor Conferences in August
From AVROBIO, Inc.
Via Business Wire
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
AVROBIO to Present at the JMP Securities Life Sciences Conference
From AVROBIO, Inc.
Via Business Wire
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
AVROBIO Reports First Quarter 2021 Financial Results and Provides Business Update
From AVROBIO, Inc.
Via Business Wire
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc. and Encourages Investors with Losses to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
BREAKING ALERT: Rosen Law Firm Encourages AVROBIO, Inc. Investors with Losses to Inquire About Class Action Investigation – AVRO
From The Rosen Law Firm, P.A.
Via Business Wire
AVROBIO Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease
From AVROBIO, Inc.
Via Business Wire
AVROBIO to Present Clinical and Preclinical Data at the ASGCT 24th Annual Meeting
From AVROBIO, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.